[breadcrumb_custom]

Is Bristol-Myers Squibb Co. (NYSE: BMY) a Risk-Worthy Bet for Bold Investors?

In the last trading session, 14.94 million Bristol-Myers Squibb Co. (NYSE:BMY) shares changed hands as the company’s beta touched 0.37. With the company’s per share price at $49.75 changed hands at -$0.06 or -0.12% during last session, the market valuation stood at $101.23B. BMY’s last price was a discount, traded about -47.68% off its 52-week high of $73.47. The share price had its 52-week low at $47.58, which suggests the last value was 4.36% up since then. When we look at Bristol-Myers Squibb Co.’s average trading volume, we note the 10-day average is 17.92 million shares, with the 3-month average coming to 0.96.

Bristol-Myers Squibb Co. (NYSE:BMY) trade information

Instantly BMY was in red as seen at the end of in last trading. With action 3.69%, the performance over the past five days has been green. The drop to weekly highs of 50.05 subtracted -0.12% to the stock’s daily price. The company’s shares are showing year-to-date downside of -3.04%, with the 5-day performance at 3.69% in the green. However, in the 30-day time frame, Bristol-Myers Squibb Co. (NYSE:BMY) is -0.94% down. Looking at the short shares, we see there were 31.09 million shares sold at short interest cover period of 2.03 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Bristol-Myers Squibb Co. (BMY) estimates and forecasts

Data shows that the Bristol-Myers Squibb Co. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -18.75% over the past 6 months, a -13.18% in annual growth rate that is considerably lower than the industry average of 15.50%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Bristol-Myers Squibb Co. will fall -22.90%, while the growth in revenue is estimated to hit 2.30% for the next quarter. Year-over-year growth is forecast to reach 2.20% up from the last financial year.

Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of $11.45 billion. 11 analysts are of the opinion that Bristol-Myers Squibb Co.’s revenue for the quarter ending Jun 2024 will be $11.54 billion. The company’s revenue for the corresponding quarters a year ago was $11.34 billion. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 5.13%. The 2024 estimates are for Bristol-Myers Squibb Co. earnings to decrease by -8.64%, but the outlook for the next 5-year period is at -2.63% per year.

BMY Dividends

Bristol-Myers Squibb Co. is expected to release its next quarterly earnings report on April 25. The 4.64% annual yield figure for the share gives it an annual dividend of 2.31. It is important to note, however, that the 4.64% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.

On Key

Related Posts